JPMorgan International Research Enhanced Equity (JIRE)
JIRE price chart
JIRE fund facts
Returns and risk
Cost: expense ratio
On $10,000 invested that is about $24 a year in fund costs, taken out of the fund's assets. The prospectus shows 0.29% before fee waivers.
Income: distributions
JIRE top holdings
| # | Holding | Weight |
|---|---|---|
| 1 | ASML Holding NV | 3.48% |
| 2 | Siemens AG | 1.78% |
| 3 | AstraZeneca plc | 1.69% |
| 4 | Shell plc | 1.55% |
| 5 | HSBC Holdings plc | 1.54% |
| 6 | Allianz SE | 1.51% |
| 7 | Banco Santander SA | 1.36% |
| 8 | UniCredit SpA | 1.33% |
| 9 | Nestle SA | 1.33% |
| 10 | Roche Holding AG | 1.32% |
Similar International ETFs
IDMO Invesco S&P International Deve...0.25% fee · +14.4% 1y GSIE Goldman Sachs ActiveBeta Inter...0.25% fee · +15.0% 1y HEFA iShares Currency Hedged MSCI E...0.35% fee · +18.7% 1y QINT American Century Quality Diver...0.34% fee · +15.4% 1y VPL Vanguard FTSE Pacific0.07% fee · +23.9% 1y WCMI First Trust WCM International...0.85% fee · +12.1% 1y All international ETFs →JIRE: frequently asked questions
What is JIRE?
JIRE is the JPMorgan International Research Enhanced Equity ETF, issued by JPMorgan, listed on NYSE ARCA. By our rules it is classed as "International". Its latest SEC filing lists 214 holdings.
What is the expense ratio of JIRE?
JIRE charges 0.24% a year after fee waivers (gross 0.29%), according to its prospectus filed with the SEC on 25 Feb 2026. On $10,000 that is about $24 a year in fund costs.
Does JIRE pay dividends?
Yes. JIRE paid 2.24 per share over the last 12 months, annual, a trailing yield of 2.74% on today's price. The latest ex-dividend date was 16 Dec 2025.
What does JIRE hold?
The largest holdings in the latest SEC filing are ASML Holding NV (3.5%), Siemens AG (1.8%), AstraZeneca plc (1.7%). The top 10 together make up 16.9% of the fund.
How has JIRE performed?
Total return including distributions to 22 Oct 2026: 1 year +13.0%, 3 years +19.1% a year. Past performance does not guarantee future results.
Where the numbers come from
StocksXray is for education only and is not financial advice or a recommendation to buy or sell anything. Past performance does not guarantee future results; funds can lose value.